The 3p wonder pill
Doctors in Wuhan revealed earlier this month that the death rate among Covid-19 patients taking the drug for their diabetes was significantly lower than for a similar group of patients not taking it.
Publication date: Available online 9 July 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Manash Pratim Barman, Tousifur Rahman, Krishnarjun Bora, Chandan Borgohain
Publication date: Available online 8 July 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Ashish Kumar, Anil Arora, Praveen Sharma, Shrihari Anil Anikhindi, Naresh Bansal, Vikas Singla, Shivam Khare, Abhishyant Srivastava
It ’s enough that SARS-Cov-2, the virus that causes Covid-19, can cause pneumonia, kidney failure, blood clots, arrhythmias and even heart attacks, but the potential that the virus may also lead to onset of diabetes provides a new set of implications and potential complications for survivors.
Authors: Dworakowska D, Grossman AB Abstract COVID-19, which is caused by the single-stranded RNA severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has introduced significant therapeutic dilemmas in several areas. One of these is concern regarding the use of renin-angiotensin system (RAS) inhibitors. Dysfunction of the RAS has been observed in COVID-19 patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs), are associated with improved or worse clinical outcomes, remains unclear. RAS inhibitors are currently widel...
AbstractCOVID-19 infection has tremendously impacted our daily clinical practice as well as our social living organization. Virtually all organs and biological systems suffer from this new coronavirus infection, either because the virus targets directly specific tissues or because of indirect effects. Endocrine diseases are not an exception and some of endocrine organs are at risk of direct or indirect lesion by COVID-19. Although there is still no evidence of higher predisposition to contract the infection in patients with diabetes and/or obesity, the coexistence of these conditions contributes to a worse prognosis becaus...
Conclusion: People with co-morbid conditions who are more prone to COVID-19-related deaths due to immune dysregulation are likely to benefit from consuming nutritional supplements that enhance the immune system. We recommend clinical studies to validate AFO-202 beta glucan in COVID-19 patients to prove its efficacy in overcoming a hyper-inflammation status, thus reducing the mortality, until a definite vaccine is made available.
Several comorbidities have been associated with an increased risk of severity and mortality in coronavirus disease 2019 (COVID-19), including hypertension, diabetes, cerebrovascular disease, chronic kidney disease, and chronic obstructive pulmonary disease.
Survey reveals 50% drop in child visits to emergency departments and the most common delayed diagnosis was type 1 diabetes. The consequences are greater than the risks of COVID-19 in kids, say experts.Medscape Medical News
Publication date: Available online 8 July 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Nazar Zaki, Hany Alashwal, Sahar Ibrahim
AbstractObjectivesTo determine if a specific immunomodulatory intervention reduces progression of COVID-19-related disease to organ failure or death, compared to standard of care (SoC).Trial designRandomised, parallel 3-arm (1:1:1 ratio), open-label, Phase IV platform trial of immunomodulatory therapies in patients with late stage 1 or stage 2 COVID-19-related disease, with a diagnosis based either on a positive assay or high suspicion of COVID-19 infection by clinical and/or radiological assessment.ParticipantsPatients aged 18 and over, with a clinical picture strongly suggestive of COVID-19-related disease (with/without ...